2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
The purpose of the study is to investigate how quickly and to what extent balovaptan is absorbed and eliminated from the body (pharmacokinetics) when it is administered alone or in combination with itraconazole. It will also be investigated to what…